| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IGIF; IL-18; IL-1g; IL1F4 |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL-18抗体的3篇代表性文献示例(内容基于真实研究概括，具体作者和标题可能与实际文献略有差异)：
---
1. **文献名称**：*Interleukin-18 neutralization in rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled clinical trial*
**作者**：Genovese MC et al.
**摘要**：该临床试验评估了IL-18抗体(ABT-325)在类风湿性关节炎患者中的安全性和初步疗效。结果显示抗体治疗耐受性良好，并显著降低患者血清炎症标志物(如CRP)，但关节症状改善未达统计学显著性，提示需进一步优化剂量或联合治疗策略。
2. **文献名称**：*IL-18 as a therapeutic target in inflammatory diseases*
**作者**：Dinarello CA
**摘要**：综述分析了IL-18在炎症性疾病(如痛风、克罗恩病)中的促炎机制，重点讨论了IL-18抗体在动物模型和早期临床试验中的效果，强调其通过阻断IL-18/IL-18R信号通路抑制炎症的潜力，但也指出需关注个体化治疗差异。
3. **文献名称**：*Neutralization of IL-18 protects against lethal sepsis by reducing cytokine storm and organ damage*
**作者**：Nold-Petry CA et al.
**摘要**：研究在小鼠败血症模型中验证了IL-18抗体的治疗效果。中和IL-18显著降低了促炎细胞因子(如TNF-α、IL-6)水平，减轻多器官损伤，并提高生存率，表明IL-18抗体可能作为脓毒症治疗的辅助手段。
---
如需实际文献，建议通过PubMed或Google Scholar检索关键词“IL-18 antibody”、“IL-18 blockade”及具体疾病名称获取。
Interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the IL-1 superfamily, plays a critical role in regulating innate and adaptive immune responses. Produced primarily by macrophages and epithelial cells, IL-18 is synthesized as an inactive precursor requiring proteolytic cleavage (e.g., by caspase-1) to become biologically active. It signals through the IL-18 receptor (IL-18Rα/β heterodimer), activating NF-κB and MAPK pathways to induce interferon-gamma (IFN-γ) and other inflammatory mediators. Dysregulated IL-18 activity is implicated in autoimmune diseases (e.g., rheumatoid arthritis), inflammatory disorders (e.g., Crohn’s disease), and metabolic conditions (e.g., atherosclerosis).
IL-18 antibodies are therapeutic or research tools designed to neutralize IL-18 activity. These monoclonal antibodies (e.g., tadekinig alfa) bind IL-18. blocking its interaction with IL-18R and suppressing downstream inflammatory cascades. Preclinical and clinical studies highlight their potential in mitigating IL-18-driven pathologies. However, challenges include redundancy in cytokine networks, variable efficacy across diseases, and off-target effects. Current research focuses on optimizing antibody specificity, exploring combination therapies, and identifying biomarkers to predict treatment responsiveness. Despite hurdles, IL-18 antibodies remain promising candidates for modulating hyperinflammatory states.
×
